Preparation of ONO-1301-loaded poly(lactide-co-glycolide) microspheres and their effect on nerve conduction velocity

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 3, 2011, Pages 362-368

  Hazekawa, Mai ^a   Sakai, Yoshiki ^b   Yoshida, Miyako ^a   Haraguchi, Tamami ^a   Morisaki, Tomomi ^a   Uchida, Takahiro ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Nerve condition velocity; ONO 1301; PGI2 agonist; PLGA microspheres; Sustained release

Indexed keywords

7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; OIL; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; STREPTOZOCIN; THROMBOXANE SYNTHASE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; EMULSION; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; NERVE CONDUCTION; NONHUMAN; PARTICLE SIZE; RAT; STREPTOZOCIN DIABETES; SUSTAINED DRUG RELEASE; THIGH;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DRUG CARRIERS; FEMALE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MICROSPHERES; MOLECULAR WEIGHT; NEURAL CONDUCTION; POLYGLYCOLIC ACID; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME;

EID: 79952214339     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01237.x     Document Type: Article

References (24)

1. Tanouchi T et al. Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem 1981; 24: 1149-1155. (Pubitemid 12208770)
2. Hotta N et al. Effects of beraprost sodium and insulin on the electroretinogram, nerve conduction, and nerve blood flow in rats with streptozotocin-induced diabetes. Diabetes 1996; 45: 361-366. (Pubitemid 26069052)
3. Alonso MJ et al. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994; 12: 299-306. (Pubitemid 24071950)
4. Seagal J et al. A fail-safe mechanism for negative selection of isotype-switched B cell precursors is regulated by the Fas/FasL pathway. J Exp Med 2003; 198: 1609-1619. (Pubitemid 37467174)
5. Mullerad J et al. Local delivery of IL-1 alpha polymeric microspheres for the immunotherapy of an experimental fibrosarcoma. Cancer Invest 2003; 21: 720-728. (Pubitemid 37377327)
6. Mullerad J et al. Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres. Cytokine 2000; 12: 1683-1690.
7. Sanchez A et al. Pulsed controlled-release system for potential use in vaccine delivery. J Pharm Sci 1996; 85: 547-552. (Pubitemid 26179093)
8. Roullin VG et al. Release kinetics of 5-fluorouracil-loaded microspheres on an experimental rat glioma. Anticancer Res 2003; 23: 21-25.
9. Obata H et al. Single injection of a sustained-release prostacyclin analog improves pulmonary hypertention in rats. Am J Rspir Crit Care Med 2008; 177: 195-201.
10. Cavaletti G et al. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997; 18: 137-145.
11. Cavaletti G et al. Carboplatin toxic effects on the peripheral nervous system of the rats. Ann Oncol 1998; 9: 443-447. (Pubitemid 28273039)
12. Cavaletti G et al. Distribution of paclitaxel within the nervous system of rat after repeated intravenous administration. Neurotoxicology 2000; 21: 389-393.
13. Cavaletti G et al. Effect on the peripheral nervous system of systemically administrated dimethylsulfoxide in the rat: a neurophysiological and pathological study. Toxicol Lett 2000; 118: 103-107. (Pubitemid 32008400)
14. Cavaletti G et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001; 37: 2457-2463. (Pubitemid 33097486)
15. Tradici G et al. Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp Neurol 1999; 159: 551-558.
16. Pisano C et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003; 9: 5756-5767. (Pubitemid 37499500)
17. Heya T et al. Factors influencing the profiles of TRH release from copoly (d,l-lactic/glycolic acid) microspheres. Int J Pharm 1991; 72: 199-205.
18. Yoshida T et al. Mechanism of controlled drug release from a salting-out taste-masking system. J Control Release 2008; 131: 47-53.
19. Berkland C et al. Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release 2002; 82: 137-147. (Pubitemid 34775055)
20. Ravivarapu HB et al. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm 2000; 50: 263-270.
21. Blanco-Prieto MJ et al. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres. J Control Release 2004; 96: 437-448. (Pubitemid 38553922)
22. Ogawa Y et al. In vivo release of leuprolide acetate from microcapsules prepared with polylactic acids or copoly (lactic/ glycolic) acids and in vivo degradation of these polymers. Chem Pharm Bull 1988; 36: 2576-2581.
23. Li L et al. Sustained release of erythropoietin using biodegradable gelatin hydrogel microspheres persistently lower leg ischemia. J Am Coll Cardiol 2009; 53: 2378-2388.
24. Sandor M et al. A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo. Biomaterials 2002; 23: 4413-4423.